List of Tauvid drug patents

Tauvid is owned by Avid Radiopharms Inc.

Tauvid contains Flortaucipir F-18.

Tauvid has a total of 1 drug patent out of which 0 drug patents have expired.

Tauvid was authorised for market use on 28 May, 2020.

Tauvid is available in solution;intravenous dosage forms.

Drug patent challenges can be filed against Tauvid from May, 2024.

The generics of Tauvid are possible to be released after 19 May, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8932557 AVID RADIOPHARMS INC Imaging agents for detecting neurological dysfunction
May, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 28, 2025

Drugs and Companies using FLORTAUCIPIR F-18 ingredient

NCE-1 date: May, 2024

Market Authorisation Date: 28 May, 2020

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic